Key result
Takotsubo syndrome shows mortality comparable to ACS, with persistent symptoms reported by ~80% of survivors.
Why the study?
Once considered benign and self-limiting, Takotsubo syndrome is now recognized as an acute cardiac syndrome associated with substantial in-hospital and long-term morbidity and mortality, prompting a synthesis of contemporary advances in its pathophysiology, management, outcomes, and ongoing controversies.
This contemporary review highlights that Takotsubo syndrome carries substantial morbidity and mortality comparable to acute coronary syndromes, while noting that current management remains guided by expert opinion pending the results of the first mechanism-targeted randomized trials.
Answers are grounded in this paper and cite their sources.
Supports ACS-level vigilance for Takotsubo syndrome; challenges benign perception and leaves open dedicated therapy trials.
Purpose of Review Once considered benign and self-limiting, Takotsubo syndrome (TTS) is now recognized as an acute cardiac syndrome associated with substantial in-hospital and long-term morbidity and mortality. This review synthesizes contemporary advances in TTS pathophysiology, management, outcomes, and ongoing controversies, with an emphasis on the emerging mechanistic and therapeutic landscape. Recent Findings Our mechanistic understanding of TTS has been recently refined by invasive and noninvasive studies associating coronary microvasculature functionality with disease onset and recovery, neuroimaging implicating heightened amygdala activity and altered limbic connectivity as predisposing neurobiological features, and cardiac and serologic inflammatory markers suggesting both upstream and downstream pathologic influences from immune activation. Contemporary registry data suggest that inpatient mortality and long-term outcomes in TTS patients may be comparable to those in ACS. Furthermore, small case-control data suggest that more than 80% of survivors report persistent symptoms. Data on aspirin and statin use in the absence of CAD suggest limited benefit, while β-blocker and RAASi signals remain discordant across modern registries. The first mechanism-targeted randomized trials, including BROKEN-SWEDEHEART (adenosine/dipyridamole and apixaban), CIT (cyclosporine A), and BREAKOUT (CBT and structured exercise), are now reporting or recruiting, and will provide much-needed evidence to guide future management. Summary TTS is a complex, multifactorial acute cardiac syndrome with long-term consequences, at an inflection point of mechanistic and therapeutic discovery. In the absence of randomized controlled trial data, management remains individualized and guided by expert statements. Continued international, multidisciplinary collaboration spanning cardiology, neurology, psychiatry, endocrinology, and basic science will be essential to translate emerging insights into meaningful improvements in patient outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a review in Takotsubo syndrome. Takotsubo syndrome exhibits inpatient mortality and long-term outcomes comparable to ACS, with over 80% of survivors reporting persistent symptoms in small case-control data.
Synapse has enriched 10 related papers. Consider them for comparative context: